Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8521 to 8535 of 8944 results

  1. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  2. OraQuick® HCV Rapid Antibody Test (discontinued)

    Discontinued Reference number: GID-MT117

    Medical technologies guidance
    Discontinued

  3. Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

    Discontinued Reference number: GID-MT130

    Medical technologies guidance
    Discontinued

  4. Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

    Discontinued Reference number: GID-MT163

    Medical technologies guidance
    Discontinued

  5. Microthane implants for breast reconstruction or breast augmentation (discontinued)

    Discontinued Reference number: GID-MT267

    Medical technologies guidance
    Discontinued

  6. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued Reference number: GID-MT536

    Medical technologies guidance
    Discontinued

  7. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]

    In development Reference number: GID-TA11481 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    Discontinued Reference number: GID-TA11146

    Technology appraisal guidance
    Discontinued

  9. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Discontinued Reference number: GID-TA11343

    Technology appraisal guidance
    Discontinued

  10. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  11. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  12. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Discontinued Reference number: GID-TA11466

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Discontinued Reference number: GID-TA11442

    Technology appraisal guidance
    Discontinued

  14. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  15. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Discontinued Reference number: GID-TA11486

    Technology appraisal guidance
    Discontinued